Patent Inter partes Decision O[removed]

First Page		Document Content
Date: 2010-02-23 11:40:54 Pharmacology Pharmaceutical industry Pharmaceutical sciences Bristol-Myers Squibb Cetuximab Supplementary protection certificate European Medicines Agency ImClone Systems Irinotecan Medicine Clinical research Pharmaceuticals policy		Patent Inter partes Decision O[removed] Add to Reading List Source URL: www.ipo.gov.uk Download Document from Source Website File Size: 380,42 KB Share Document on Facebook

	CRAB CTC: Phase I Study of Carfilzomib (C) and Irinotecan (I) in Relapsed Irinotecan-Sensitive Solid Tumors Susanne M. Arnold, MD1; Kari Chansky, PhD2; Markos Leggas, PhD1; Michael Thomson, MD3; John Hamm, MD4; Ra DocID: 1rySF - View Document
	MA En fase II-undersøgelse af irinotecan ugentligt til patienter med lokal avanceret eller metastatisk HER2positiv brystkræft og øget antal kopier af topoisomerase 1 (TOP1) genet Sponsor: DocID: 1rl7Y - View Document
	MA En fase II-undersøgelse af irinotecan ugentligt til patienter med lokal avanceret eller metastatisk HER2negativ brystkræft og øget antal kopier af topoisomerase 1(TOP1) genet. Sponsor: DocID: 1r6Cl - View Document
	fluorouracil pain relief, fluorouracil opthalmic solution fluorouracil generic alternative, fluorouracil package insert ic fluorouracil, wikipedia fluorouracil genital warts and fluorouracil. fluorouracil msds, fluoroura DocID: 1fzbO - View Document
	ZALTRAP® (ziv-aflibercept) DocID: 17zTi - View Document